SCHEMBL30748757

SCHEMBL30748757

COc1ccc(CNc2nc(CO)nc3c2C(C)(C)CN3c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
APP P05067 3/20 0.40
TP53 P04637 1/20 0.37
SLC2A1 P11166 1/20 0.37
HTR2B P41595 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748721 0.87 CCNE2 (0.43) ALDH1A1KDM4EHTTSMN1; SMN2APP
SCHEMBL31691289 0.85 KDM4E (0.41) ALDH1A1KDM4EHTTSMN1; SMN2APP
SCHEMBL31691227 0.85 APP (0.40) ALDH1A1KDM4EHTTSMN1; SMN2APP
SCHEMBL30748758 0.85 APP (0.37) APP
SCHEMBL30748731 0.81 PIK3CB (0.45) ALDH1A1KDM4EHTTSMN1; SMN2LMNA
SCHEMBL30749122 0.81 TNK2 (0.36) KDM4EPOLB
SCHEMBL30749001 0.78 TDP1 (0.38) ALDH1A1SMN1; SMN2APPTSHRCCNE2
SCHEMBL30748853 0.74 POLB (0.36) SMN1; SMN2MAPK1POLB
SCHEMBL30749065 0.73 PDE4A (0.39) ALDH1A1KDM4ESMN1; SMN2APPTSHR
SCHEMBL30748936 0.72 CCNE2 (0.41) APPTP53LMNACCNE2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALDH1A1 256/4885KDM4E 2102/4885HTT 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.